Table 2.

Treatment-Related Treatment-Emergent Adverse Events in > 10% of Total Patients.

Cohort A
CTCAE Term	Grade 1	Grade 2	Grade 3	Total (N =16)
	n (%)	n (%)	n (%)
Diarrhea	9	3	1	13 (81)
Rash	6	1	1	8 (50)
Stomatitis	4	1	2	7 (44)
Dry skin	3	3	0	6 (37)
Nausea	5	0	1	6 (37)
Fatigue	3	1	1	5 (31)
Dermatitis acneiform	0	4	0	4 (25)
Decreased appetite	1	1	1	3 (19)
Conjunctivitis	0	0	2	2 (13)
Dehydration	0	1	1	2 (13)
Dysgeusia	2	0	0	2 (13)
Elevated AST	1	0	1	2 (13)
Elevated Alk Phos	1	1	0	2 (13)
Maculopapular rash	1	1	0	2 (13)
Oral pain	2	0	0	2 (13)
Peripheral neuropathy	1	0	1	2 (13)
Vomiting	1	1	0	2 (13)
Xerosis	2	0	0	2 (13)
Cohort B
CTCAE Term	Grade 1	Grade 2	Grade 3	Total (N = 22)
Diarrhea	11	3	2	16 (73)
Rash	7	3	1	11 (50)
Nausea	7	2	0	9 (41)
Dry skin	5	2	0	7 (32)
Paronychia	4	3	0	7 (32)
Fatigue	4	2	0	6 (27)
Decreased appetite	4	1	0	5 (23)
Pruritis	4	0	1	5 (23)
Stomatitis	3	1	1	5 (23)
Dermatitis acneiform	2	1	0	3 (14)
Mucosal inflammation	0	3	0	3 (14)